Cutaneous adverse events following treatment with third-generation EGFR tyrosine kinase inhibitors

被引：0
|
作者：
Li Pomi, Federica [1 ]
Vaccaro, Federico [2 ]
Borgia, Francesco [1 ]
Irrera, Natasha [1 ]
Vaccaro, Mario [1 ]
机构：
[1] Univ Messina, Dept Clin & Expt Med, Sect Dermatol, I-98125 Messina, Italy
[2] Univ Modena & Reggio Emilia, Dept Dermatol, Modena, Italy
来源：
ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY | 2024年 / 159卷 / 02期
关键词：
D O I：
10.23736/S2784-8671.23.07781-2
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：212 / 214
页数：3
相关论文
共 50 条
  • [31] Emerging strategies to overcome resistance to third-generation EGFR inhibitors
    Kunyu Shi
    Guan Wang
    Junping Pei
    Jifa Zhang
    Jiaxing Wang
    Liang Ouyang
    Yuxi Wang
    Weimin Li
    Journal of Hematology & Oncology, 15
  • [32] Emerging strategies to overcome resistance to third-generation EGFR inhibitors
    Shi, Kunyu
    Wang, Guan
    Pei, Junping
    Zhang, Jifa
    Wang, Jiaxing
    Ouyang, Liang
    Wang, Yuxi
    Li, Weimin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [33] Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
    Alissa J. Cooper
    Lecia V. Sequist
    Jessica J. Lin
    Nature Reviews Clinical Oncology, 2022, 19 : 499 - 514
  • [34] Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
    Cooper, Alissa J.
    Sequist, Lecia, V
    Lin, Jessica J.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (08) : 499 - 514
  • [35] Therapeutic potential of ERK inhibitors in overcoming acquired resistance to third generation EGFR tyrosine kinase inhibitors
    Li, Yiting
    Qian, Guoqing
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Sun, Shi-Yong
    CANCER RESEARCH, 2019, 79 (13)
  • [36] Targeting DNA topoisomerase II to manage acquired resistance to third generation EGFR tyrosine kinase inhibitors in the treatment of EGFR mutant NSCLC
    Chen, Zhen
    Vallega, Karin A.
    Wang, Dongsheng
    Quan, Zihan
    Fan, Songqing
    Wang, Qiming
    Leal, Ticiana A.
    Ramalingam, Suresh S.
    Sun, Shi-Yong
    CANCER RESEARCH, 2024, 84 (06)
  • [37] EGFR tyrosine kinase inhibitors in the treatment of cancer
    Barker, AJ
    MEDICINAL CHEMISTRY INTO THE MILLENNIUM, 2001, (264): : 140 - 147
  • [38] Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
    Breccia, Massimo
    Colafigli, Gioia
    Molica, Matteo
    Alimena, Giuliana
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (04) : 525 - 533
  • [39] First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
    Tatineni, Vineeth
    O'Shea, Patrick J.
    Ozair, Ahmad
    Khosla, Atulya A.
    Saxena, Shreya
    Rauf, Yasmeen
    Jia, Xuefei
    Murphy, Erin S.
    Chao, Samuel T.
    Suh, John H.
    Peereboom, David M.
    Ahluwalia, Manmeet S.
    CANCERS, 2023, 15 (08)
  • [40] New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer
    Fassunke, J.
    Heydt, C.
    Michels, S.
    Van Veggel, B.
    Mueller, F.
    Keul, M.
    Dammert, M. A.
    Schmitt, A.
    Smit, E. F.
    Kast, S.
    Wolf, J.
    Buettner, R.
    Sos, M. L.
    Rauh, D.
    Merkelbach-Bruse, S.
    ANNALS OF ONCOLOGY, 2019, 30
12345